SCHEMBL30486270

SCHEMBL30486270

NC(=O)c1nn(-c2c(F)cccc2Cl)cc1Nc1ccc(C(=O)N2CCCC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 8/20 0.50
▸ JAK2 O60674 5/20 0.50
▸ JAK1 P23458 4/20 0.50
▸ JAK3 P52333 4/20 0.50
▸ MAPT P10636 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GRM5 P41594 5/20 0.39
▸ CCNT1 O60563 1/20 0.39
▸ CDK4 P11802 1/20 0.39
▸ CCND1 P24385 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ CDK6 Q00534 1/20 0.39
▸ CDK11A Q9UQ88 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26773365 1.00 TYK2 (0.50) TYK2JAK2JAK1JAK3MAPT
SCHEMBL26773367 0.99 TYK2 (0.49) TYK2JAK2JAK1JAK3MAPT
SCHEMBL30486259 0.99 TYK2 (0.49) TYK2JAK2JAK1JAK3MAPT
SCHEMBL26773320 0.93 MAPT (0.47) TYK2JAK2JAK1JAK3MAPT
SCHEMBL26777206 0.92 HPGD (0.47) TYK2JAK2JAK1JAK3MAPT
SCHEMBL26773322 0.92 HPGD (0.47) TYK2JAK2JAK1JAK3MAPT
SCHEMBL30486380 0.92 CCNT1 (0.49) TYK2JAK2JAK1JAK3MAPT
SCHEMBL30486356 0.92 TYK2 (0.61) TYK2JAK2JAK1JAK3MAPT
SCHEMBL26773164 0.92 TYK2 (0.61) TYK2JAK2JAK1JAK3MAPT
SCHEMBL26773206 0.92 CCNT1 (0.49) TYK2JAK2JAK1JAK3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4192464-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Origenis GmbH (DE) 2023-06-14 — — EP claimed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, MAPKAPK2, MAP3K20 TYK2 1/4885JAK2 89/4885JAK1 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback